Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma.
- Resource Type
- Academic Journal
- Authors
- Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: chris_labaki@dfci.harvard.edu.; Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Saad E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Eid M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Lalani AK; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.; Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Braun DA; Center of Molecular and Cellular Oncology (CMCO), Yale School of Medicine, New Haven, CT, USA.
- Source
- Publisher: Elsevier Health Science Country of Publication: United States NLM ID: 8709473 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-1977 (Electronic) Linking ISSN: 08898588 NLM ISO Abbreviation: Hematol Oncol Clin North Am Subsets: MEDLINE
- Subject
- Language
- English
Patients with metastatic clear cell renal cell carcinoma (mccRCC) experience highly heterogeneous outcomes when treated with standard-of-care systemic regimens. Therefore, valid biomarkers are needed to predict the clinical response to these therapies and help guide management. In this review, the authors outline relevant and promising biomarkers for patients with mccRCC receiving systemic therapies, with a focus on immunotherapy-based regimens.
(Copyright © 2023 Elsevier Inc. All rights reserved.)